Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm (Nasdaq: KPTI) announced financing and capital-structure transactions expected to provide approximately $100 million of flexibility and additional capital, extending its cash runway into the second quarter of 2026. The transactions include new term loans, convertible-note exchanges, a private placement expected to raise about $8.75 million, and warrant repricings to an exercise price of $6.64. Preliminary Q3 2025 revenue is expected at $42–$44M with U.S. XPOVIO net product revenue of ~$32M. Cash as of Sept 30, 2025 is estimated at ~$46M before financing proceeds. Top-line Phase 3 SENTRY myelofibrosis data remain on track for March 2026.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 333 restricted stock units (RSUs) to one newly-hired employee. The grant was made on September 30, 2025, under the company's 2022 Inducement Stock Incentive Plan.
The RSUs will vest over a three-year period, with one-third of the units vesting annually on the grant date anniversary. Vesting is contingent upon the employee's continued service with Karyopharm.
Karyopharm Therapeutics (Nasdaq: KPTI) has completed enrollment in its Phase 3 SENTRY trial, evaluating selinexor in combination with ruxolitinib for JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients with top-line results expected in March 2026.
The study aims to assess if selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis. The trial's co-primary endpoints include spleen volume response rate ≥35% at week 24 and the average change in absolute total symptom score over 24 weeks versus baseline. Patients were randomized 2-to-1 to receive either 60mg weekly selinexor with ruxolitinib or placebo with ruxolitinib.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 466 restricted stock units (RSUs) to two newly-hired employees as of August 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan.
The RSUs will vest over three years, with 33 1/3% vesting annually. Additionally, the RSUs include acceleration provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI) reported Q2 2025 financial results with total revenue of $37.9 million, including U.S. XPOVIO net product revenue of $29.7 million, up 6% year-over-year. The company reaffirmed its full-year 2025 total revenue guidance of $140-155 million while updating U.S. XPOVIO revenue guidance to $110-120 million.
Key developments include the imminent completion of patient screening for the Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026. However, the company faces financial challenges with $52.0 million in cash as of June 30, 2025, down from $109.1 million at year-end 2024. Karyopharm is actively exploring financing transactions and strategic alternatives to extend its cash runway beyond the October 2025 maturity of its convertible notes.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day. Investors can access the call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with accompanying slides will be available on the company's investor relations website.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 333 restricted stock units (RSUs) to one newly-hired employee as of July 31, 2025. The RSUs will vest over three years, with 33 1/3% vesting annually on the grant date anniversary.
The grant was made under the company's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting annually. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, the RSUs include provisions for immediate full vesting in case of employment termination under specific conditions following a change in control event.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
